Eli Lilly & Co. (LLY) Misses Q2 EPS by 46c, Revenue Misses
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts LLY Hot Sheet
Price: $1,273.46 -2.54%
EPS Growth %: -20.2%
Financial Fact:
Acquired in-process research and development: 0
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
EPS Growth %: -20.2%
Financial Fact:
Acquired in-process research and development: 0
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Eli Lilly & Co. (NYSE: LLY) reported Q2 EPS of $1.25, $0.46 worse than the analyst estimate of $1.71. Revenue for the quarter came in at $6.49 billion versus the consensus estimate of $6.85 billion.
GUIDANCE:
Eli Lilly & Co. sees FY2022 EPS of $7.90-$8.05, versus the consensus of $8.08.
For earnings history and earnings-related data on Eli Lilly & Co. (LLY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Tompkins Financial (TMP) Tops Q3 EPS by 5c
- Healthcare Stocks Rushing Higher, with Oncology Push, Breakout Test, and Lilly’s Next Growth Chapter
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
